GAMMA Investing
MLTX icon

GAMMA Investing’s MoonLake Immunotherapeutics MLTX Stock Holding History

GAMMA Investing’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$164 Hold
14
– – ﹤0.01% 4292
2026
Q2 		$273 Buy
+14
New +$254 ﹤0.01% 4058
2025
Q4 		– Sell
-6
Closed -$43 – 4116
2025
Q3 		$43 Buy
+6
New +$313 ﹤0.01% 3834

Other funds holding MLTX

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
BWM
BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return
BC
Bulwark Capital Fernandina Beach, Florida $189M AUM 7.81% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GAMMA Investing's MLTX Position: Q3 2026 in Review

GAMMA Investing held its MoonLake Immunotherapeutics (MLTX) position steady in Q3 2026 at 14 shares worth $164. The position accounts for ﹤0.01% of the portfolio, ranked #4292.

GAMMA Investing first reported a position in MLTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $273 in Q2 2026. 9 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • GAMMA Investing held 14 shares of MoonLake Immunotherapeutics worth $164 as of Q3 2026.
  • GAMMA Investing left its MoonLake Immunotherapeutics share count unchanged in Q3 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4292 holding.
  • GAMMA Investing first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • GAMMA Investing's MoonLake Immunotherapeutics position peaked at $273 in Q2 2026.
  • 9 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.